These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22533884)

  • 1. [Prognostic significance of morphology in multiple myeloma].
    Al-Sahmani M; Trnavská I; Antošová M; Antošová L; Kissová J; Kaisarová B; Adam Z; Buliková A; Penka M; Hájek R
    Klin Onkol; 2012; 25(2):103-9. PubMed ID: 22533884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of morphological assessment of plasma cells in multiple myeloma.
    Al-Sahmani M; Trnavska I; Sevcikova S; Antosova M; Antosova L; Kissova J; Adam Z; Pour L; Nemec P; Greslikova H; Krejci M; Zahradova L; Bulikova A; Penka M; Hajek R
    Neoplasma; 2011; 58(6):554-60. PubMed ID: 21895410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
    Minarik J; Scudla V; Bacovsky J; Zemanova M; Pika T; Ordeltova M; Langova K
    Neoplasma; 2010; 57(1):8-14. PubMed ID: 19895166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
    Krejci M; Gregora E; Straub J; Minarik J; Scudla V; Adam Z; Krivanova A; Pour L; Zahradova L; Buchler T; Mayer J; Hajek R
    Ann Hematol; 2011 Dec; 90(12):1441-7. PubMed ID: 21380511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
    del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
    South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
    Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
    Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
    Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New treatment strategy of multiple myeloma for cure].
    Murakami H; Handa H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
    Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J
    Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
    Corre J; Labat E; Espagnolle N; Hébraud B; Avet-Loiseau H; Roussel M; Huynh A; Gadelorge M; Cordelier P; Klein B; Moreau P; Facon T; Fournié JJ; Attal M; Bourin P
    Cancer Res; 2012 Mar; 72(6):1395-406. PubMed ID: 22301101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma].
    Chen SL; Qiu LG; Jiang B; Yu L; Zhong YP; Gao W
    Zhonghua Nei Ke Za Zhi; 2011 Apr; 50(4):291-4. PubMed ID: 21600146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.